Alchemab Therapeutics secured an additional €29.3 million (£25 million/$34 million) in Series A funding from the British Business Bank, bringing their total Series A to €127.8 million (£109 million). This funding will expand their proprietary antibody sequence dataset from 500 million to one billion and advance additional pipeline candidates. The investment, the British Business Bank's largest in a life sciences company, will support Alchemab's goal of developing first-in-class antibody therapeutics.